GleamWall
中文EN

MOLN MOLECULAR PARTNERS AG IFRS

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1745114 · Reporting currency CHF · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-29.4%
TTM net income YoY12.8%
TTM EPS YoY15.9%
Revenue 3-yr CAGR-20.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,231.7%
Net margin-1,087.4%
FCF margin-1,206.3%
EBITDA margin-1,184.1%

Returns

ROE-34.0%
ROA-30.3%
ROIC (approx.)-51.8%
Asset turnover0.03x

Leverage & solvency

Liabilities / assets10.7%
Debt / equity0.00x
Current ratio14.31x
Interest coverage-1,610.97x

Cash quality & payout

Operating cash flow / net income1.10x
Accruals ratio2.9%
Payout ratio—
Capex / revenue14.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: CHF 2025Q2*2025-06-302024Q2*2024-06-302023Q2*2023-06-302022Q2*2022-06-30
Income statement
Revenue01.55M415,00011.76M
R&D expense10.71M13.09M11.63M12.57M
SG&A expense3.99M4.44M4.67M5.48M
Operating income-17.32M-15.98M-15.88M-6.29M
Interest expense3.50M18,0001.19M241,000
Pretax income-20.40M-15.08M-15.99M-4.52M
Income tax0000
Net income-20.40M-15.08M-15.99M-4.52M
EPS (basic)-0.56-0.46-0.49-0.14
EPS (diluted)-0.56-0.46-0.49-0.14
Weighted avg. shares (diluted)37.39M33.18M32.83M32.50M
Balance sheet
Cash & equivalents81.97M64.06M63.24M114.94M
Short-term investments32.51M93.44M154.95M170.12M
Receivables3.60M3.37M1.51M2.58M
Current assets120.57M165.60M223.86M291.49M
PP&E, netmay include right-of-use assets (IFRS)3.68M4.89M6.36M7.52M
Intangibles10,000122,000277,000291,000
Total assets124.25M170.62M230.49M299.29M
Current liabilities12.90M11.36M15.67M23.31M
Total liabilities17.59M15.05M24.52M33.42M
Shareholders' equity106.66M155.57M205.98M265.87M
Cash flow statement
Operating cash flow————
Stock-based compensation1.23M1.13M1.31M1.52M

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· Amounts are in the company's reporting currency, CHF, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.